Cerebras Raises IPO Range to $150-$160 — 20x Oversubscribed

Update: CBRS quote page is live

Cerebras now has a live TECHi quote page for CBRS, with the current price, chart, market data, news, and related analysis. This article remains available as IPO background, so earlier filing or pricing references should be read in historical context.

Track it here: live TECHi CBRS quote page.

Cerebras Systems lifted the price range on its IPO to $150 to $160 a share ahead of pricing, up from the initial $115 to $125 range filed in early May, after orders ran more than 20 times the available shares. At the high end the deal raises up to $4.8 billion and values the wafer-scale AI chipmaker at up to $48.8 billion fully diluted — a roughly 84% jump from the $26.6 billion implied at the original midpoint.

The bump is the headline. The math underneath is the story.

Cerebras printed $510 million in 2025 revenue with a 47% reported net margin (on an accounting basis that included non-recurring gains) and a GAAP operating loss of roughly $146 million. At $48.8 billion, the deal is pricing at approximately 96x trailing sales — a multiple that requires the company to compound revenue at greater than 70% per year for the next three years just to grow into a 25x sales figure that resembles peer infrastructure software.

What changed between the original filing and the bump

The early-May S-1/A filed with the SEC first set the range at $115-$125 with 28 million Class A shares offered. CNBC then reported the bump to $150-$160 late in the cycle after the underwriter book — led by Morgan Stanley, Citigroup, Barclays and UBS — closed at greater than 20 times oversubscribed. At the top of the new range the implied valuation could reach $48.8 billion fully diluted, with up to $4.8 billion in gross proceeds.

That is a roughly 28% increase in offer price while share count stayed flat at 28 million. The reflexive read is that demand simply pulled the price higher; the more useful read is that the lead syndicate now believes the post-IPO float is positioned to clear higher even after lockup-window dilution. Cerebras' Class A structure plus warrant overhang from earlier financing rounds mean the public float is materially smaller than the diluted share count suggests — a structural underwrite for early after-market support.

The 96x sales multiple in context

At ~$48.8 billion versus $510 million revenue:

• Nvidia trades at roughly 25x forward sales — the bull-case multiple for the entire AI-chip cohort.
• Palantir trades around 45x forward sales — already a stretched outlier (see the Palantir AI-revenue audit on whether the multiple is defensible).
• Astera Labs, the closest AI-infrastructure pure-play, trades near 35x forward sales.

96x trailing is not 96x forward — Cerebras' 2026 revenue trajectory could compress the multiple meaningfully if the OpenAI buildout converts on schedule. But "compress meaningfully" still leaves the stock at roughly 40-50x forward sales in the bull case. The pricing requires both flawless OpenAI ramp execution AND a sustained AI capex cycle through 2028 — neither of which is in the underwriter's hands once the lockup unwinds.

OpenAI is the entire growth thesis

Cerebras' anchor commercial relationship is OpenAI's 750-megawatt low-latency compute commitment through 2028, valued at more than $20 billion across the multi-year window. The deal includes a $1 billion working-capital loan tied to delivery milestones, which means OpenAI is not only a customer — it is effectively financing Cerebras' inventory ramp.

Two things follow from that structure:

1. Concentration risk is severe. A material slip in OpenAI's own capex cadence — driven by Stargate funding gaps, Microsoft partnership friction, or a shift toward in-house silicon at the buyer — flows directly into Cerebras' top line with no diversification cushion. The same hyperscaler capex story is already pulling memory suppliers into a record pricing cycle, but Micron has dozens of HBM customers spread across Nvidia, AMD, and the hyperscalers; Cerebras has effectively one anchor.
2. AWS distribution provides some optionality — Cerebras CS-3 systems are deploying into AWS data centers and via Amazon Bedrock — but AWS has not disclosed a committed dollar volume comparable to the OpenAI tranche schedule.

The implied math: if OpenAI accounts for 70%+ of FY26 revenue (a reasonable inference from the multi-tranche delivery schedule), then a single-customer pause has a multiple-compressing impact on the stock that no AI-infrastructure peer faces in the same severity.

The cohort signal: AI-hardware IPOs are pricing at extreme multiples

Cerebras is the largest of three high-profile AI-infrastructure IPOs queued for spring 2026. The bigger story is cohort multiple expansion:

• The original range implied $26.6 billion at 52x sales — already premium versus 2023-2024 chip IPO comps.
• The new range implies $48.8 billion at 96x sales — closer to 2021 SPAC-era pricing than to traditional chip IPO discipline.

For investors holding Nvidia, Broadcom, AMD, or other AI-cohort names at 25-30x forward, the Cerebras print is the multiple ceiling that justifies (or breaks) the bull case for the entire AI-hardware cohort. A successful pricing at $160 plus a 30%+ first-week pop sustains the cohort's premium. A break-issue with a 20%+ giveback would compress comparable multiples across the sector within days.

What to watch from here

Three checkpoints around the IPO pricing:

1. Final price + first-day allocation tier — whether shares hit institutional accounts or retain a retail-heavy book determines lockup-window volatility.
2. OpenAI capex commentary in the next round of Microsoft and Oracle hyperscaler earnings — those reveal whether the buyer's underlying capex curve is intact.
3. Q1 FY26 revenue print from Cerebras post-listing — the cleanest test of whether the OpenAI tranche schedule converted on plan.

The pre-bump Cerebras IPO walkthrough covers the wafer-scale architecture, the second-attempt narrative, and the operating-loss-versus-net-income reconciliation. The bump shifts the question from "is the company real?" — settled at $510M revenue with hyperscaler validation — to "does the public-market multiple price the customer concentration AND the FY27 execution risk?" That one is still open.

Editor's risk note: Editorial analysis, not investment advice. IPO pricing is volatile by design — final terms, allocation tiers, and post-listing lockups all materially change the risk profile from what is described above. Verify current filings and consult a qualified advisor before trading.